Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma

(2015) Graham P. Collins et al.   BRITISH JOURNAL OF HAEMATOLOGY

Abstract C197: Accurins improve the pharmacokinetics, pharmacodynamics, tolerability and anti-tumor activity of the AKT inhibitor MK-2206

(2015) Louise Cadzow et al.   MOLECULAR CANCER THERAPEUTICS

Albumin-bound paclitaxel in solid tumors: clinical development and future directions

(2015) Madappa Kundranda et al.   Drug Design Development and Therapy

Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug Conversion

(2014) A. V. Kalra et al.   CANCER RESEARCH

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia

(2013) Hagop M. Kantarjian et al.   CANCER

Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML

(2013) Hagop M. Kantarjian et al.   Clinical Lymphoma Myeloma & Leukemia

Safety and feasibility of targeted agent combinations in solid tumours

(2013) Sook Ryun Park et al.   Nature Reviews Clinical Oncology

Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale

(2012) E. Komlodi-Pasztor et al.   CLINICAL CANCER RESEARCH

Aurora kinase inhibitors: Progress towards the clinic

(2012) Madhu Kollareddy et al.   INVESTIGATIONAL NEW DRUGS

An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

(2012) K. E. Hook et al.   MOLECULAR CANCER THERAPEUTICS

Formation of Stable Nanocarriers by in Situ Ion Pairing during Block-Copolymer-Directed Rapid Precipitation

(2012) Nathalie M. Pinkerton et al.   MOLECULAR PHARMACEUTICS

Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile

(2012) J. Hrkach et al.   Science Translational Medicine

Nanoparticle Delivery of Cancer Drugs

(2011) Andrew Z. Wang et al.   Annual Review of Medicine

Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors

(2010) D. S. Boss et al.   ANNALS OF ONCOLOGY

Development and characterization of nanoparticulate formulation of a water soluble prodrug of dexamethasone by HIP complexation

(2010) Ripal Gaudana et al.   JOURNAL OF MICROENCAPSULATION

Mitotic drivers—inhibitors of the Aurora B Kinase

(2009) Nicholas Keen et al.   CANCER AND METASTASIS REVIEWS

Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model

(2009) Lena E. Friberg et al.   INVESTIGATIONAL NEW DRUGS